You are here:


Annual Report

We are proud to present Intravacc’s Annual Report 2020. This report reflects a remarkable year for Intravacc, for many reasons.


2020 –  a challenging and dynamic year

The year 2020 was a remarkable and challenging year for all of us around the globe. In one way or the other, we were all affected by the Covid-19 pandemic. However, for most companies in the vaccine business, this pandemic also triggered the start of an exciting period.

This was true for Intravacc, as well. During this dynamic year, we successfully continued our efforts to become a standalone private contract development and manufacturing organization (CDMO). With our state-of-the-art infrastructure, equipment, experienced staff and unique market position we are able to bridge the gap between vaccine concepts and late-stage clinical trials.

Building Intravacc 2.0

In 2020, together we set out to build Intravacc 2.0. This included a restructure of the organization, implementation of a business matrix, a design controlled product development processes and the establishment of a business development department which will engage with our existing and future customers to expand our services and product pipeline. We also rebranded the company and launched a new website to match our ambition to become a leading CDMO within the vaccine industry.

The future: Intravacc’s plans for 2021

We are very pleased with our progress in 2020 and expect 2021 to be another very exciting year of growth and accomplishment. We will advance our strategic plan to become a leading CDMO providing high quality vaccine development services and bringing innovative vaccine concepts to the market.

The investment we have made and will continue to make in our vaccine platforms, the focus on quality, vaccine development and clinical validation, as well as the early success of our Covid-19 vaccine concepts, progress with our oncology strategy and increasing number of commercial service projects is clearly recognized by our industry players.

We believe that we are in the very early stages of a sustained growth cycle, with the ultimate goal of offering healthcare providers and governments a wide range of affordable preventive and therapeutic vaccines.


The Supervisory Board and the Board of Directors of Intravacc sincerely appreciates the support and contributions of our stakeholders, scientific collaborators, the medical community, Ministry of Public Health and other stakeholders who have entrusted us to deliver on our mission of developing innovative vaccines to contribute to the reduction of human disease burden

Download Annual Report 2020


Contact our

A team of 140+ specialists is at your disposal here in Bilthoven. Contact us to see how we can bring your vaccine concept ready for in-human trials.


Subscribe to our news update

Stay up to date with the latest developments, and be the first to receive our news updates and announcements.